Rachel Lunini, PA
Medical · Las Vegas, NVNPI 1497091870
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 318 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by AbbVie at 24.6% of the total.
Across 318 payments — averaging $21.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Forte Bio-pharma LLC$836
- AstraZeneca$747
- Novo Nordisk$402
- Lilly USA, LLC$269
- plus $2K from 26 others
What the payments were for
- Food & beverage$6,879100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 96 | $1,698 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 48 | $1,010 |
| Forte Bio-pharma LLC | 20 | $836 |
| AstraZeneca | 29 | $747 |
| Novo Nordisk | 17 | $402 |
| Lilly USA, LLC | 11 | $269 |
| Collegium Pharmaceutical, Inc. | 10 | $245 |
| Bayer | 17 | $203 |
| ANI Pharmaceuticals, Inc. | 7 | $168 |
| IBSA Pharma Inc. | 7 | $167 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $140 |
| Kyowa Kirin, Inc. | 2 | $129 |
| Protega Pharmaceutials Inc | 7 | $127 |
| Scilex Pharmaceuticals Inc. | 6 | $99 |
| Averitas Pharma Inc. | 4 | $89 |
| Dexcom, Inc. | 5 | $87 |
| Redhill Biopharma Inc. | 4 | $81 |
| Amarin Pharma, Inc. | 3 | $49 |
| Amgen | 2 | $45 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $37 |
| Exact Sciences | 2 | $32 |
| Gilead | 1 | $32 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| Pfizer | 1 | $27 |
| Boston Scientific | 1 | $27 |
| Idorsia Pharmaceuticals US Inc | 1 | $25 |
| GSK | 1 | $21 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| Nalu Medical, Inc. | 1 | $18 |
| Impel Pharmaceuticals Inc. | 1 | $15 |
| Inogen, Inc. | 1 | $12 |
| SPR Therapeutics, Inc | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,894 in reported general payments places this provider in the 85th percentile of 250 medical providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 140 | $175,663 |
| RelistorMethylnaltrexone Bromide | 57 | $147,978 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 730 | $70,884 |
| FarxigaDapagliflozin Propanediol | 51 | $67,161 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $43,009 |
| ProlateOxycodone Hcl/Acetaminophen | 14 | $37,446 |
| VraylarCariprazine Hcl | 21 | $27,938 |
| UbrelvyUbrogepant | 22 | $26,353 |
| LyricaPregabalin | 25 | $26,073 |
| MounjaroTirzepatide | 19 | $20,972 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 618 | $19,932 |
| JanuviaSitagliptin Phosphate | 12 | $19,781 |
| TrulicityDulaglutide | 21 | $19,700 |
| Xtampza ErOxycodone Myristate | 47 | $19,319 |
| JardianceEmpagliflozin | 15 | $19,018 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $402 | $175,663140 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $1,010 | $147,97857 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $747 | $79,83467 claims |
| AbbVieVraylar, Ubrelvy, Qulipta | $1,698 | $70,97559 claims |
| PfizerLyrica, Nurtec Odt, Eliquis | $27 | $56,55456 claims |
| GSKTrelegy Ellipta | $21 | $43,00947 claims |
| Lilly USA, LLCMounjaro, Trulicity | $269 | $40,67240 claims |
| Forte Bio-pharma LLCProlate | $836 | $37,44614 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca | $245 | $34,31076 claims |
| Redhill Biopharma Inc.Movantik | $81 | $16,87435 claims |
| IBSA Pharma Inc.Licart | $167 | $12,94418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 250 medical providers in Nevada.
Other medical in Las Vegas
- John NotabartoloLas Vegas$284K
- Rachel BowersLas Vegas$29K
- Spencer MeierLas Vegas$24K
- Megan WieselLas Vegas$19K
- Tai PhamLas Vegas$16K
- Eric HilmesLas Vegas$15K
- Wardon OjedapoLas Vegas$12K
- Melchor GochiocoLas Vegas$11K
- Keesha KaplanLas Vegas$11K
- Adelbert WadsworthLas Vegas$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.